A recent study revealed that first-line tyrosine kinase inhibitors (TKIs) brigatinib, alectinib, and lorlatinib “demonstrated real-world effectiveness versus crizotinib,” while “comparable effectiveness was observed for brigatinib versus…
Study Compares Effectiveness of First-Line TKIs in Patients With ALK+ NSCLC and Brain Metastases
